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Case reportWe describe the case of a patient with prostate cancer, ascites, omental and bone metastases, an
extremely rare clinical variant that warrants further investigation, and review the relevant
literature.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Prostate cancer is the second cause of cancer related deaths in
men, despite a decrease in incidence and mortality rates in theUnited States by 2.4% from 2001 to 2005 [1]. Hematogenous
metastases are present in 35% of patients with prostate cancer,
with most frequent involvement sites being bone (90%), lung
(46%), liver (25%), pleura (21%), and adrenals (13%) [2–4].
The risk of systemic dissemination increases sharply in the
presence of regional and para-aortic lymph node involvement.
The peritoneum is an extremely rare metastatic site for pros-
tatic adenocarcinoma, with only a few cases published to date.
We present a rare case of a patient who presented to our
department with peritoneal disease, massive ascites and locally
advanced prostate cancer. A review of the literature was also
performed.
Fig. 1 Prostate biopsy (A) and Prostate-speciﬁc antigen (PSA) immunochemistry (B). (A) Histology of prostate obtained after
prostatectomy showing neoplastic cells arranged in diffuse and rarely in cribriform pattern. Cytoplasm is pale to clear and contain oval
nuclei with prominent nucleoli. H + E. (B) Prostate-speciﬁc antigen (PSA) immunohistochemistry.
Fig. 2 (A) Abdominal CT scan showing peritoneal/omental thickening, (B) enlarged prostate gland and (C) ascites.
Fig. 3 Cytology of ascitic ﬂuid and prostate acid phosphatase (PAP) test. Material with moderate cellularity and atypical, small-sized
cells positive to (A) PSAP and (B) PAP.
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Table 1 Review of the Literature of 16 cases with prostate cancer and ascites.
Author/year Age Other metastases
(apart of peritoneal or omentum)
Treatment Response of
ascites to treatment
Outcome
Pre-ascites After-ascites
Rapoport et al./1968 [6] 76 Lymph nodes NM 5FU+ thiotepa (intraperitoneal) Progression Death at 3 months
45 None NM Orchiectomy NM Death
Megalli et al./1973 [7] 58 None None RT, Diethylstilbestrol Remission Alive at 6 months
Biegel et al./1990 [8] 29 Bones Refusal of therapy Progression Death at 1 month
Disdier et al./1990 [9] 78 None None Nilutamide Remission NM
Catton et al./1992 [10] 63 Visceral, lymph nodes Orchiectomy Remission Death at 13 months
Saif et al./1999 [11] 70 None RT, leuprolide, leutamide,
bicalutamide, thalidomide
NM Progression Disease progression
Tsai et al./2001 [12] 68 Rectal wall Toremifene Interferon Progression Death at 16 weeks
Amin et al./2002 [13] 83 Lymph nodes Antiandrogens Hormonal withdrawal Progression Death at 6 weeks
Kehinde et al./2002 [14] 76 None None TURP, Orchiectomy Remission 18 months post-orchiectomy
with no recurrent ascites
Lapoile et al./2004 [15] 80 Bones, others RT, triptorelin, aminoglutethimide
and hydrocortisone
None Progression Death at 12 weeks
Appalaneni et al./2004 [16] 60 Bones, lymph nodes RT, LHRH agonist, antiandrogen None Progression Death at 6 weeks
Brehmer et al./2007 [17] 75 Lymph nodes
(no ascites present)
Bicalutamide Goserelin, Bicalutamide Remission 14 months no recurrence
Madaan et al./2007 [18] 75 Lymph nodes Goserelin Diethylstilboestrol, ASA Progression Death within 4 months
Zagouri et al./2009 [19] 75 None Goserelin, bicalutamide and
docetaxel estramustine
Docetaxel Remission NM
Benedict et al./2010 [20] 67 None Hormonal therapy Docetaxel Remission NM
Ani et al./2013 [21] 57 Lymph nodes, Bones Bicalutamide LHRH agonist – Stable disease NM
Present case 76 Lymph nodes TURP+Goserelin, bicalutamide Docetaxel Remission Alive at 6 months
NM: not mentioned, RT: radiotherapy, TURP: transurethral resection of the prostate, ASA: acetylsalicylic acid.
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A 76 year old patient was admitted to our department in Feb-
ruary 2010, for investigation of massive ascites. A diagnosis of
prostatic adenocarcinoma had been made 16 years ago. At that
time, the patient denied radical surgical or radiotherapeutic
treatment and was managed with only transurethral resection
and combined androgen blockade with bicalutamide and
leuprolide. Seven months before the current admission bladder
inﬁltration with the development of bilateral hydronephrosis
and pelvic/paraaortic lymph node enlargement were docu-
mented on computerized tomography (CT), along with rise
of serum PSA (286.4 ng/ml) as well as moderate renal dysfunc-
tion (serum creatinine 3,0 mg/dl). New prostatic biopsies were
obtained (Fig. 1). Nephrostomies were placed in both kidneys
and bicalutamide was withdrawn. Within the following weeks,
episodes of hematuria and massive ascites, complicated by
constipation and malaise, prompted the patient to visit our
department.
Family history was remarkable for a brother with leukemia
and a son with sarcoma. He was a smoker (30 pack/years), with
no consumption of alcohol and no allergies. Physical examina-
tion conﬁrmed the presence of massive ascites and a ﬁrm
prostate enlargement on rectal exam. Both nephrostomies were
functioning normally. Laboratory investigation showed
increased serum PSA levels of 432.9 ng/ml and serum creatinine
concentrations at 3.1 mg/dl. An abdominopelvic CT showed
bladder inﬁltration, omental thickening and massive ascites
(Fig. 2). Large volume paracentesis of the ascitic ﬂuid conﬁrmed
the diagnosis ofmetastatic adenocarcinomawith the presence of
atypical, small-sized cells positive for PSA and prostate-speciﬁc
acid phosphatase (PSAP) (Fig. 3). Bone scintigraphy was posi-
tive for bone metastases. Intravenous docetaxel 60 mg/m2 and
daily oral prednisone 5 mg bid were commenced, resulting in
symptomatic palliation, clinical improvement, resolution of
ascites and a decrease of serum PSA levels (100 ng/ml). After
having completed nine cycles of treatment, the patient is
asymptomatic 10 months after initiation of therapy.
Discussion
Prostatic cancer is metastatic in 35% of cases, with a marked
predilection for bony spread. Growth factors immobilized on
bony matrix and adhesive molecules expressed in marrow stro-
mal cells as well as production of PSA and urokinase-type
plasminogen activator (u-PA) are some of the factors impli-
cated for preferential homing of prostate cancer cells to the
bones in 90% of metastatic cases [5]. Other less common sites
are lung, liver, pleura and adrenals. Skin, optic nerve, mandi-
ble, testicles, penis, pituitary gland, thyroid, salivary glands are
some of the uncommon sites reported in the literature. The
omentum as metastatic site is extremely rare, with only 15
cases presented until now [6–21] (Table 1). The age of these
patients at diagnosis ranged between 29 and 76 years, the
majority of them had a high risk localized adenocarcinoma
at diagnosis and only three presented with bone metastases.
The time gap between diagnosis and ascites was from 1 to
16 years [6–21]. Ascites responded in 7 out of 16 cases, 4 to
endocrine manipulations and 3 to chemotherapy. Responders
survived up to 18 months while nonresponders died between
1 and 4 months. In our case the patient presented with similarclinical ﬁndings, as he was treated for 16 years for localized
disease and was stable until seven months before admission.
We conﬁrmed peritoneal involvement by cytology and abdom-
inopelvic CT. Strikingly, the clinical, imaging and biochemical
response to docetaxel/prednisone was remarkable already even
after the 1st cycle of therapy. Clinicians should be aware of this
rare clinical variant of prostate cancer which should be metic-
ulously worked up in order to exclude other malignancies.
Occasionally palliation can be achieved with hormonal treat-
ment or chemotherapy regimens already used for metastatic
prostate cancer.Conclusions
With this article, we added an additional case of an unusual
manifestation of advanced prostate cancer presented with per-
itoneal metastases and massive ascites. Oncologists should
draw their attention to this rare clinical presentation of meta-
static prostatic cancer.
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